Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regeneron supplies gene technology to Sanofi-Aventis

This article was originally published in Scrip

Executive Summary

Regeneron Pharmaceuticals is to receive a minimum annual payment of $4.3 million from Sanofi-Aventis for the use of its gene technology platform, Velocigene. The payment, to be made over five years, will be for knock-out and transgenic models of gene function for target genes that Sanofi-Aventis identifies. Sanofi-Aventis will use these models for its internal research programmes outside the antibody collaboration that the two companies started in November 2007 for the development of human therapeutic antibodies (Scrip No 3317, p7).

Related Companies

UsernamePublicRestriction

Register

SC004233

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel